Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7456 to 7470 of 7707 results

  1. Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

    Discontinued [GID-TA10242]

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]

    Discontinued [GID-TA11005]

    Technology appraisal guidance
    Discontinued

  3. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued [GID-TA11399]

    Technology appraisal guidance
    Discontinued

  4. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued [GID-TA11421]

    Technology appraisal guidance
    Discontinued

  5. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    Discontinued [GID-TA10316]

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    Discontinued [GID-TA11024]

    Technology appraisal guidance
    Discontinued

  7. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    In development [GID-TA10843] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1018.

    Technology appraisal guidance
    Published
    16 December 2021

  9. Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]

    In development [GID-TA11472] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued [GID-TA11209]

    Technology appraisal guidance
    Discontinued

  11. Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants (IPG270)

    This guidance has been updated and replaced by NICE interventional procedures guidance 795.

    Interventional procedures guidance
    Published
    23 July 2008

  12. EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)

    This advice has been updated and replaced by NICE diagnostics guidance 34.

    Medtech innovation briefing
    Published
    10 November 2015

  13. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    In development [GID-TA11165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease (IPG606)

    This guidance has been updated and replaced by NICE interventional procedures guidance 796.

    Interventional procedures guidance
    Published
    28 February 2018

  15. myCOPD for managing chronic obstructive pulmonary disease (MTG68)

    This guidance has been updated and replaced by NICE health technology evaluation 19, which covers using myCOPD for self-management of chronic obstructure pulmonary disease (COPD), and NICE health technology evaluation 18, which covers using myCOPD for pulmonary rehabilitation.

    Medical technologies guidance
    Published
    31 March 2022